Shi C, Tan Y, Hu S, Qin Y, et al. Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study. Diabetes Obes Metab 2024 Mar 18. doi: 10.1111/dom.15552.
PMID: 38497231